Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Genetics of multiple sclerosis: swimming in an ocean of data.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
[Nicolau syndrome after administration of glatiramer acetate].
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
BTG Commences Phase IIa Study of Multiple Sclerosis
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Dynamic regulatory network controlling TH17 cell differentiation.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Neuroprotective effect of masitinib in rats with postischemic stroke.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Laquinimod in multiple sclerosis.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.

Pages